I. AMENDMENTS TO THE CLAIMS:

1. (Original) A method for treatment of gastrointestinal tumors by administering compounds, having the formula:

or their salts, where:

 $A = R(COX)_t$ wherein t is an integer 0 or 1;

X = O, NH, NR_{1C} wherein R_{1C} is a linear or branched alkyl having from 1 to 10 C atoms;

R is chosen from the following groups:

Group I A), where t = 1,

where:

R_{II5} is H, a linear C₁-C₃ alkyl, or a branched C₁-C₃ alkyl;

R_{II6} has the same structure as R_{II5},

 R_{II1} , R_{II2} and R_{II3} are each hydrogen, linear C_1 - C_6 alkyl, branched C_1 - C_6 alkyl, C_1 - C_6 alkoxy, Cl, F, or Br;

R_{II4} has the same structure as R_{II1} or is bromine;

Group II A) chosen from the following:

where, when t = 1, R is

$$R_{1a} - \int_{R_{3a}}^{R_{2a}}$$

where R_{2a} and R_{3a} are H, a linear C₁-C₁₂ alkyl, a branched C₁-C₁₂ alkyl, or allyl, with the proviso that when one of the two is allyl the other is H;

 R_{1a} is chosen from the subgroup II Aa) consisting of

wherein:

in the residue of formula (IV):

 R_{III1} is H or SR_{III3} where R_{III3} contains from 1 to 4 linear or branched C atoms; and R_{III2} is H or hydroxy;

in the residue of formula (XXI):

 R_{xxio} is H, a linear alkyl having 1-6 carbon atoms, a branched alkyl having from 1 to 6 carbon atoms, a C_1 - C_6 alkoxy-carbonyl bound to a C_1 - C_6 carboxyalkyl, or a C_1 - C_6 alkanoyl, optionally substituted with halogen, benzyl or halobenzyl, benzoyl or halobenzoyl;

 R_{xxi} is H, halogen, hydroxy, CN, a C_1 - C_6 alkyl optionally containing OH groups, a C_1 - C_6 alkoxy, acetyl, benzyloxy, SR_{xxi2} where R_{xxi2} is a C_1 - C_6 alkyl; a perfluoroalkyl having a 1-3 C atoms, a C_1 - C_6 carboxyalkyl optionally containing OH groups, NO_2 , sulphamoyl, dialkyl sulphamoyl with the alkyl having from 1 to 6 C atoms, or difluoroalkylsulphonyl with the alkyl having from 1 to 3 C atoms;

 R_{xxil} is halogen, CN, a C_1 - C_6 alkyl optionally containing one or more OH groups, a C_1 - C_6 alkoxy, acetyl, acetamido, or benzyloxy,

SR_{III3} is as above defined, a perfluoroalkyl having from 1 to 3 C atoms, hydroxy, a carboxyalkyl having from 1 to 6 C atoms, hydroxy, a carboxyalkyl having from 1 to 6 C

atoms, NO2, amino, mono- or dialkylamino having from 1 to 6 C atoms, sulphamoyl, a dialkyl sulphamoyl having from 1 to 6 C atoms, difluoroalkylsulphamoyl; or Rxxi together with R_{xxil} is an alkylene dioxy having from 1 to 6 C atoms;

In the residue of formula (XXXV):

Ar is phenyl, hydroxyphenyl optionally mono- or polysubstituted with halogen, an alkanoyl or alkoxy having from 1 to 6 C atoms, a trialalkyl having from 1-6 C atoms, cyclopentyl ohexyl o-heptyl, thienyl, furyl, furyl containing OH, or pyridyl;

Subgroup II Ab) consisting of:

(IVXXX)

(XXXXII)

wherein:

when IIIa) contains -CH(CH₃)-COOH it is known as pranoprofen: α -methyl-5H-(1) benzopyran (2,3-b) pyridine-7-acetic acid;

when residue (XXX) contains -CH(CH₃) -COOH it is known as bermoprofen: dibenz (b,f) oxepin-2-acetic acid;

residue (XXXI) is known as CS-670: 2-(4-2(2-oxo-1-cyclohexylidenemethyl) phenyl) propionic acid, when the radical is -CH(CH₃) -COOH;

- 9 - Application Serial No. 10/686,907 Attorney-Docket No. 026220-00039 when residue (XXXII) contains group -CH₂COOH it is known as pemedolac;

when residue (XXXIII) is saturated with -CH₂COOH it is known as pyrazolac: 4-(4-chlorophenyl)-1-(4-fluorophenyl) 3-pyrazolyl acid derivatives;

when residue (XXXVI) is saturated with -CH(CH₃)-COO- it is known as zaltoprofen;

when residue (XXXVII) is CH₂-COOH it derives from the known mofezolac: 3,4-di p-methoxyphenyl) isoxazol-5-acetic acid;

Group IIIA), where t = 1,

wherein:

at least one of R_{lvd} and R_{lvd1} is H and the other a linear or branched C_1 - C_6 alkyl, or difluoroalkyl with the alkyl having from 1-6 C atoms, or R_{lvd} and R_{lvd} jointly form a methylene group;

 R_{IV} has the following structure:

where:

in the residue of formula (II):

R_{IV-II} is selected from the group consisting of an alkyl having from 1 to 6 C atoms, a cycloalkyl having from 3 to 7 C atoms, an alkoxymethyl having from 1 to 7 C atoms, a trifluoroalkyl having from 1 to 3 C atoms, vinyl, ethynyl, halogen, an alkoxy having from 1 to 6 C atoms, a difluroalkoxy with the alkyl having from 1 to 7 C atoms, an alkoxymethyloxy having from 1 to 7 C atoms, an alkylmethylthio with the alkyl having from 1 to 7 C atoms, cyano,

, or

difluoromethylthio, a substituted phenyl-, and phenylalkyl with the alkyl having from 1 to 8 C atoms;

 R_{IV-III} is a C_2 - C_5 alkyl, a C_2 or C_3 alkyloxy, allyloxy, phenoxy, phenylthio, a cycloalkyl having from 5 to 7 C atoms, optionally substituted at position 1 by a C_1 - C_2 alkyl; Group IV A)

where A = RCOO, t = 1,

Group V A) chosen from the following:

Subgroup V Aa) residues chosen from the following, where t = 1

(V Aa1)

(V Aa2)

(V Aa3)

(V Aa4)

subgroup V Ab), residue, where t = 1:

subgroup V Ac), residue, where t = 0 and R is as follows:

(V Ac1)

(V Ac2)

(V Ac3)

(V Ac4)

rial No. 10/686,907 No. 026220-00039

subgroup V Ad) residues, where t = 1 and R is as follows:

(V Ad2)

(Eba V)

- 16 -

Application Serial No. 10/686,907 Attorney-Docket No. 026220-00039

(V Ad4)

subgroup Ae) residues, where t = 1 and R is as follows:

- 17 -

(▼ Ae3)

(V Ae4)

(V Ae5)

(V Ae6)

- 18 - Application Serial No. 10/686,907 Attorney-Docket No. 026220-00039

Application Serial No. 10/686,907 Attorney-Docket No. 026220-00039 wherein:

in compounds (V Ac1) Rvac1 attached to the oxygen atom in position 2 of the benzene ring of the N - (4-nitro-phenyl)methansulphonamide can be phenyl or cyclohexane, when Rvac1 is phenyl the residue is that of nimesulfide;

in compounds (V Ac2) the residue of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-bezopyran-4-one has been shown;

in compounds (V Ac3) the atom X₄ that links the radical 2,4-difluorothiophenyl to position 6 of the indanone ring of the residue 5-methanesulfonamido-1-indanone can be sulfur or oxygen;

Group VIA), where t = 1,

OCOR₃

$$(R_2)_{nI} (R_1)_{nI}$$
(Ib)

where:

 R_1 is group OCOR₃; where R_3 is methyl, ethyl or a linear or branched C_3 - C_5 alkyl, or the residue of a single-ring heterocycle having 5 or 6 atoms which can be aromatic, partially or totally hydrogenated, containing one or more heteratoms independently chosen from O, N and S; R_2 is hydrogen, hydroxy, halogen, a linear or whenever possible branched alkyl having from 1 to 4 C atoms, a linear or whenever possible branched alcoxyl having from 1 to 4 C atoms; a linear or whenever possible branched perfluoroalkyl having from 1 to 4 C atoms, for example trifluoromethyl, nitro, amino, mono- or di (C_{1-4}) alkylamino; R_1 and R_2 jointly are the dioxymethylene group, with the proviso that when X = NH, then X_1 is ethylene and $R_2 = H$; R_1 cannot be OCOR₃ at position 2 when R_3 is methyl; nl being an integer from 0 to 1;

X₁ in formula A-X₁-NO₂ is a bivalent connecting bridge chosen from the following:

- YO

where Y is a linear or branched C₁-C₂₀ alkylene, or an optionally substituted cycloalkylene having from 5 to 7 carbon atoms;

where n₃ is an integer from 0 to 3;

where nf is an integer from 1 to 6;

where R_{1f} = H or CH_3 and nf is an integer from 1 to 6.

- 2. (Original) The method according to Claim 1, in which R is selected from groups IIA) and VIA).
- 3. (Withdrawn) The method according to Claim 1, in which R is as defined by group IIA), wherein $R_{3a} = H$, $R_{2a} = CH_3$, R_{1a} is the formula (IX) and X = O.

- 4. (Original) The method according to Claim 1, in which R is as defined by group VIA) (formula Ia), wherein R_1 is the group OCOR₃ with R_3 = CH₃, R_2 = H and X = O; R_1 is in the ortho position to CO.
- 5. (Original) A method for treatment of gastrointestinal tumors, according to Claim 1, by administering compounds having the following formulas:

6. (Canceled)